Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyprogesterone Caproate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyprogesterone Caproate SCHEMBL5330 | 1.00 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL21497316 | 1.00 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL14649335 | 1.00 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL94788 | 1.00 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL16812894 | 1.00 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL17517045 | 1.00 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL5425550 | 0.99 | LMNA (0.98) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL353516 | 0.99 | LMNA (0.98) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL14656870 | 0.99 | LMNA (0.98) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL17519899 | 0.98 | LMNA (0.96) | LMNANR3C1SMN1; SMN2HIF1APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116077416-B | Oral preparation containing progestogen and preparation method and application thereof | 深圳埃格林医药有限公司 | 2024-12-06 | — | — | CN | claimed |
| US-20240285649-A1 | PROGESTOGEN FORMULATIONS FOR USE IN MODULATING A CYTOKINE STORM MEDIATOR | SHENZHEN EVERGREEN THERAPEUTICS CO LTD (CN) | 2024-08-29 | — | — | US | claimed |
| US-20230321052-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | XOMA (US) LLC | 2023-10-12 | — | — | US | claimed |
| WO-2023150726-A2 | THREE-TIERED RISK STRATIFICATION FOR SPONTANEOUS PRETERM BIRTH | NX PRENATAL INC. (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2023107796-A1 | OPHTHALMIC FORMULATIONS FOR MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-15 | — | — | WO | claimed |
| US-20230181599-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHENZHEN EVERGREEN THERAPEUTICS CO LTD (CN) | 2023-06-15 | — | — | US | claimed |
| WO-2023078073-A1 | NOVEL ORAL PREPARATION CONTAINING PROGESTOGEN, AND PREPARATION METHOD AND USE | 深圳埃格林医药有限公司 | 2023-05-11 | — | — | WO | claimed |
| EP-3344258-B1 | TREATING AUTO-IMMUNE AND AUTO-INFLAMMATORY DISEASES | SHENZHEN EVERGREEN THERAPEUTICS CO LTD (CN) | 2023-05-10 | — | — | EP | claimed |
| CN-116077416-A | Novel oral preparation containing progestogen and preparation method and application thereof | 深圳埃格林医药有限公司 | 2023-05-09 | — | — | CN | claimed |
| EP-4144351-A1 | HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVES AS INHIBITORS OF THE PROSTAGLANDIN F RECEPTOR | ObsEva S.A. (CH) | 2023-03-08 | — | — | EP | claimed |
| EP-2117554-A2 | PROGESTERONE FOR THE PREVENTION OF PRETERM BIRTH | Columbia Laboratories (Bermuda) Limited (BM) | 2009-11-18 | — | — | EP | claimed |
| WO-2008096122-A2 | PROGESTERONE FOR THE PREVENTION OF PRETERM BIRTH | COLUMBIA LABORATORIES (BERMUDA) LIMITED (BM) | 2008-08-14 | — | — | WO | claimed |
| US-20080188829-A1 | PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PRETERM BIRTH | ALLERGAN SALES, LLC | 2008-08-07 | — | — | US | claimed |
| EP-1936376-A2 | Screening and treatment methods for prevention of preterm delivery | ADEZA BIOMEDICAL CORPORATION (US) | 2008-06-25 | — | — | EP | claimed |
| WO-2006048639-A1 | HYDROGEL DELIVERY VEHICLE | CONTROLLED THERAPEUTICS (SCOTLAND) LIMITED (GB) | 2006-05-11 | — | — | WO | claimed |
| EP-0801561-B1 | COMPOSITION AND METHODS FOR TRANSDERMAL DELIVERY OF ACID-LABILE DRUGS | NOVEN PHARMA (US) | 2005-04-06 | — | — | EP | claimed |
| US-20040266025-A1 | Screening and treatment methods for prevention of preterm delivery | CYTYC CORPORATION | 2004-12-30 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4014988-A | Method for treating hypermenorrhea with uterine therapeutic system | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321052-A1 | ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF | PGF, PTGER1, PTGER4 | PGR 310/4885LMNA 1791/4885NR3C1 360/4885 |
| US-20230181599-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHBG, PGR, CYP17A1 | PGR 2/4885LMNA 847/4885NR3C1 42/4885 |
| US-20240285649-A1 | PROGESTOGEN FORMULATIONS FOR USE IN MODULATING A CYTOKINE STORM MEDIATOR | IL17A, CRH, IL15 | PGR 11/4885LMNA 2763/4885NR3C1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.